Our initial focus is in end-stage liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available. For patients with end-stage liver disease (cirrhosis) the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. At Resolution, we are developing a macrophage cell therapy product with first-in-class potential to treat patients at risk of hepatic decompensation, with the aim of preventing further decompensations and avoiding the need for a liver transplant.